Humacyte, Inc. — Form SCHEDULE 13D/A
Filed August 18, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 22/100
What the filing says
Fresenius Medical Care Holdings Inc. filed an amended Schedule 13D/A regarding its beneficial ownership in Humacyte, Inc. The filing date is 2026-08-18. The specific details of the amended stake (share count, percentage ownership, or transaction details) are not disclosed in the header/metadata provided; the actual amendment content is not included in the submission text excerpts shown.
Why this rating
Schedule 13D amendment is routine disclosure of ownership changes. Without concrete details (share count, % change, dollar amount), cannot assess materiality. No transaction or event triggered; purely procedural filing.
See more from August 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.